

Lynne Haber, Oliver Kroner
Toxicology Excellence for Risk Assessment



Beyond Science and Decisions: From Problem Formulation to Dose-Response



Alliance for Risk Assessment

www.allianceforrisk.org

- A collaboration of organizations dedicated working together to solve public health issues
 - Improve communication among groups
 - Provide transparency in development of products
 - Foster harmonization and consistency in risk assessments
 - Share costs and human resources

Expert Panel



- Michael Bolger, U.S. Food and Drug Administration
- James S. Bus, The Dow Chemical Company
- John Christopher, CH2M/Hill
- Rory Conolly, U.S. Environmental Protection Agency
- Michael Dourson, Toxicology Excellence for Risk Assessment
- *Adam M. Finkel, UMDNJ School of Public Health
- William Hayes, Indiana Department of Environmental Management (Workshop II only)
- R. Jeffrey Lewis, ExxonMobil Biomedical Sciences, Inc.
- Randy Manning, Georgia Department of Natural Resources (Workshop III only)
- **Bette Meek**, University of Ottawa (Chairperson)
- Paul Moyer, Minnesota Department of Health (MDH) (Workshop II only)
- *Greg Paoli, Risk Sciences International
- Rita Schoeny, U.S. Environmental Protection Agency
- *On NAS Science and Decisions panel

Collaborators





IDEM













American Chemistry

Council⁻

















































www.environcorp.com










Case Study Process

- Process encouraged engagement from wide variety of stakeholders
- Proposed in brainstorming prior to first workshop
- Initial vetting and review in breakout groups at first workshop
- Presentations at second workshop
- Additional case studies and issues identified at second workshop
- 30+ case studies proposed
- 24 case studies presented and reviewed by panel

Case Study Process & Dose-Response Framework

- Need for systematic organization of methods and ability to identify gaps
- Need for framework as a resource for risk assessors
- An interactive tool draft framework was developed by panel members and interested workshop participants to aid in selecting dose-response methods based on:
 - Problem formulation; data availability; regulatory context
- The framework was used by the panel to prioritize new case studies for third workshop, focusing on 3 topic areas:
 - Problem formulation
 - Mode of action
 - Endogenous & background exposures

Figure S-1 from NAS (2009) *Science and Decisions: Advancing Risk Assessment*.



Dose-Response Framework



PHASE 1: Problem Formulation & Scoping

(Adapted from NAS [2009] Figure S-1)

- What problem(s) are associated with existing environmental conditions?
- If existing conditions appear to pose a threat to human or environmental health, what options exist for altering those conditions?
- Under the given decision context, what risk and other technical assessments are necessary to evaluate the possible risk management options?

Qualitative Decision

Quantitative Screening
Decision

In-Depth Assessment

Figure 5-8 from Assemble Health Effects Data (NAS 2009) Endpoint Assessment Identify adverse effects, focusing on those of concern for exposed. populations Identify precursors and other upstream indicators of toxicity Identify gaps - for example, endpoints or lifestages under assessed or not assessed MOA Assessment Vulnerable Populations Background Exposure Assessment Assessment (for each endpoint of concern) Identify potentially vulnerable Identify possible Research MOAs for groups and individuals, background exogenous and endpoints observed in considering endpoints, the endogenous exposures animals and humans potential MOA, background Conduct screening level Evaluate the sufficiency of rate of health effect, and other exposures and analysis focusing the MOA evidence risk factors on high end exposure groups Evaluate endogenous processes contributing to MOA Conceptual Model Selection Develop or select conceptual model: From linear conceptual models unless data sufficient to reject low dose linearity From non-linear conceptual models otherwise Dose Response Method Selection Select dose response model and method based on: Dose-Response Modeling Conceptual model and Results Reporting Data availability 10 Risk management needs for form of risk characterization

Quantitative Screening Decision

(Adapted from NAS [2009] Figure 5-8)

Assemble Health Effects Data

Endpoint Assessment

- . Use available data to identify adverse effects, focusing on those of concern for exposed populations
- · Consider strengths and uncertainties in data

MOA Assessment

- What are expected targets, based on chemical structure, available data, and related chemicals?
- What is known about MOA for related chemicals?



Vulnerable Populations Assessment

- Assessment
- Use available data to assist in the risk management decision



Background Exposure Assessment

 Use available data to assist in the risk management decision

Dose-Response Evaluation

- Consider available dose-response information on chemical of interest and related chemicals
- Place chemical in appropriate category based on hazard, doseresponse, or dose-response and exposure information



Results Reporting

Dose Response Framework

The risk assessor is guided to methods that address key issues, such as:

- Mode of action assessment
- Vulnerable population assessment
- Endogenous/background exposure
- Dose-response methods reflecting different
 - Conceptual models
 - Data availability
 - Risk management needs

Methods Presentation

Methods linked to case studies to illustrate realworld application

- Summaries that briefly describe method, provide key references, outline the minimum data requirements, describe strengths and weaknesses
 - Summary addresses the method's potential to address human variability, sensitive populations, and background exposures or responses.
- In depth full case study
- Workshop presentation slides

Quantitative Screening Methods

- Tiered approach case study (includes threshold of concern approach)
- Low-dose Extrapolation from BMD(L)
- Threshold of toxicological concern
- Threshold of regulation
- Screening-level safe dose
- Structure-activity relationships and read-across
- Quantitative SAR

DOSE-RESPONSE EVALUATION

Note: In general, the methods used here apply substantially health-protective assumptions to avoid type II errors*

Method Case Studies

- Tiered Approach Case Study (includes threshold of concern approach)
- Low Dose Extrapolation from the BMD(L)
- ★ Threshold of Toxicological Concern
 - Deriving Health-Protective Values for Evaluation of Acute Inhalation Exposures for Chemicals with Limited Toxicity Data Using a Tiered Screening Approach Grant R.L., Phillips T., Ethridge S.
 - Summary
 - · Case Study
 - Presentation Slides

- Screening-level safe dose
- E Structure-activity relationship (SAR) and read-across

In-Depth Dose-Response Assessment



In-Depth Assessment

(Adapted from NAS [2009] Figure 5-8)

Assemble Health Effects Data

Endpoint Assessment

- Identify adverse effects, focusing on those of concern for exposed populations
- · Identify precursors and other upstream indicators of toxicity
- Identify gaps for example, endpoints or lifestages under-assessed or not assessed
 (Data gaps are noted qualitatively and addressed quantitatively with <u>uncertainty factors</u>)

MOA Assessment (for each endpoint of concern)

- Research MOAs for endpoints observed in animals and humans
- Evaluate the sufficiency of the MOA evidence
- Evaluate endogenous processes contributing to MOA



Vulnerable Populations Assessment

Identify potentially vulnerable groups and individuals, considering endpoints, the potential MOA, background rate of health effect, and other risk factors



Background Exposure Assessment

- Identify possible background exogenous and endogenous exposures
- Conduct screening level exposures and analysis focusing on high end exposure groups

Dose-Response Method Selection

Select dose-response model based on:

- Conceptual model
- Data availability
- Risk management needs for form of risk characterization



Dose-Response Modeling and Results Reporting

MOA ASSESSMENT

(for each endpoint of concern)

- Research MOAs for endpoints observed in animals and humans
- Evaluate the sufficiency of the MOA evidence
- Evaluate endogenous processes contributing to MOA

Method Case Studies

Sufficiency of MOA evidence/research MOAs - MOA/HRF/KEDRF Butadiene

- Butadiene Ovarian Case Study
- Butadiene Cancer Case Study
- Ethanol Case Study
- Low-Dose Evaluation for Genotoxicity
 - Assessment of Low-Dose Dose-Response Relationships (Non-linear or Linear) for Genotoxicity, Focused on Induction of Mutations & Clastogenic Effects Moore M., Pottenger L., Zeiger E., and Zhou T.
 - Case Study Summary
 - Addendum
 - Presentation
- Dioxin Case Study (Key Events Dose Response Framework)

Endogenous Processes Contributing to MOA

- Butadiene Ovarian Case Study
- Biologically Based Dose Response to Address Endogenous Exposure Formaldehyde
- Endogenous/Background DNA Damage
- Kinetic Variability Based on PON1 Polymorphism (Integrated with PBPK)- Chlorpyrifos

Workshop Results

- 24 case studies were developed by outside parties and reviewed by the expert panel.
 - Additionally evolved methodologies in specific areas
 - Explored crosscutting issues raised by NAS (2009), including---but not limited to---problem formulation, Mode of Action (MOA), background & endogenous exposures, & dose response methods
- Paper on workshop series and framework in preparation

Workshop Results

- The expert panel determined that:
 - A wide range of problem formulations or decision contexts exist for which different dose-response analysis techniques are needed.
 - It is important for risk assessors to explain criteria applied in the choice of a particular dose-response or risk assessment approach, and how the dose-response results will be used in a risk management decision.
 - Additional case studies would be useful on topics such as:
 - Combined exposures
 - Value of information
 - Illustrating an entire risk assessment, from problem formulation to conclusion
 - In vitro to in vivo extrapolation

Next Steps

- Framework will be "evergreen," growing and evolving over time. It will be updated with additional methods and guidance documents, illustrated by case studies and with papers addressing and resolving cross-cutting issues.
- The National Library of Medicine has expressed interest in hosting the Framework. Some structural changes needed
- A standing panel will be created to meet twice a year to review additional case studies and issue/resolution papers.
 - Nominations and self-nominations welcome Haber@tera.org
- Additional sponsors/participants will be invited to join in the overall effort.

Framework

- ARA Dose Response Framework (working beta)
 - http://www.allianceforrisk.org/workshop/fra mework/ problemformulation.html
- Part 2 of the symposium presents several sample methods and case studies